Sentence examples for favorable progression from inspiring English sources

We observed that most patients presented a favorable progression of oral intake.

Shah et al. [ 35] defined three relevant regions, of which R2 and R3 encompass DMR1 and 2, and methylation of two of these three regions were associated with favorable progression free survival in their population of 44 glioblastoma patients treated with RT and concomitant and adjuvant TMZ.

In phase III trials, gp100 vaccination showed favorable progression-free survival for metastatic melanoma[7].

It is widely considered that a major molecular response (MMR) is the goal of therapy, as it is associated with a favorable progression-free survival [ 15].

However, in a cohort of metastatic breast cancer patients who received tamoxifen treatment, high BCAR3 mRNA levels were associated with favorable progression-free survival outcome.

With a median follow-up of 20.7 months, the patients treated with gefitinib showed a highly favorable progression-free survival (PFS) of 9.7 months and OS of 24.3 months.

Similarly, univariate analyses also suggest oral contraceptives (ever versus never) was associated with more favorable progression-free survival (hazard ratio (HR) 0.71 (95%% confidence interval (CI): 0.61, 0.83); p < 0.0001) (Fig.  2).

CYP2C19*2 was associated with a favorable progression-free survival in patients with metastatic breast cancer treated with tamoxifen [ 10], while carriers of a CYP2C19*17 allele who were treated with adjuvant tamoxifen had a favorable disease-free survival compared to non- CYP2C19*17 carriers [ 11].

However, the prognosis for tumors in the hypothalamic/chiasmatic region (where the pilomyxoid variant occurs) and tumors where complete surgical resection was not carried out (or could not be carried out because of location) has less favorable progression-free and overall survival [ 14].

Bacterial vaginosis is a heterogeneous syndrome characterized by diverse microbiota, some of which might be essential "founder" species necessary to establish an environment favorable to progression to BV.

Furthermore, the time interval between peak hazard rates of responders and nonresponders in the BPC cohort is narrower than that for the NovoTTF-100A cohort, suggesting that NovoTTF-100A responders had a slightly more favorable tumor progression profile than BPC chemotherapy responders.